Skip to main content
Premium Trial:

Request an Annual Quote

DNAPrint Kits Will Incorporate Exiqon Technology

NEW YORK, Aug. 28 - DNAPrint Genomics today said it will incorporate into certain of its pharmacogenomics and forensics tests a modified DNA made by Danish microarray firm Exiqon.

The technology, called Locked Nucleic Acid, is a DNA analog that is said to have favorable binding affinity toward complementary DNA and the ability to discriminate between matching and mismatching target sequences, according to DNAPrint.

 

Sarasota, Fla.-based DNAPrint said it hopes the LNA technology will improve the performance of its kits and services. The company did not say how much it paid for the non-exclusive rights to use the LNA.

 

Exiqon, based in Denmark, is privately held.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.